# V1 Empirics Check — openai/gpt-oss-120b (Variant C)

**Model:** openai/gpt-oss-120b
**Variant:** C
**Date:** 2026-03-29T13:22:56.338724

---

**1. Idea Fidelity**

The paper stays true to the original manifest.  
- **Data:** It uses the ARCOS transaction‑level file (≈178 M rows) and constructs the “high‑dose share” (≥30 mg oxycodone) exactly as proposed.  
- **Identification:** The authors implement a county‑level DiD with Florida counties as the treated group and neighboring Georgia/Alabama counties as controls, centred on the July 2011 full‑enforcement date of HB 7095. They also discuss the staggered‑PDMP angle (though the main body focuses on the Florida pill‑mill law, which matches the manifest’s “anchor case”).  
- **Outcome:** They analyse three composition measures – high‑dose share, average mg per pill, and the oxycodone‑to‑hydrocodone ratio – all of which were listed in the manifest.  
Overall, the paper pursues the intended research question and does not omit any core element of the proposed design.

---

**2. Summary**

The paper examines how Florida’s 2010‑2011 pill‑mill crackdown altered the *dosage‑strength composition* of oxycodone shipments, rather than merely the volume. Using county‑month panels of ARCOS data and a difference‑in‑differences (DiD) design (pill‑weighted regressions), the author finds a 9.3‑percentage‑point decline in the share of ≥30 mg tablets, driven by high‑volume counties, and documents a clear “boom‑bust” pattern in an event‑study framework. The work highlights dosage composition as a potentially early‑warning indicator of diversion activity.

---

**3. Essential Points**

1. **Inference with Only Three Clusters**  
   The paper clusters standard errors at the *state* level (FL, GA, AL). With just three clusters, the conventional cluster‑robust variance estimator is unreliable, and the permutation‑test p‑value (1/3) is uninformative. The authors must adopt inference methods appropriate for few clusters (e.g., wild cluster bootstrap, Cameron‑Gelbach‑Miller t‑statistics, or randomization inference with a larger set of placebo states). At present the reported p‑values (e.g., 0.007) are misleading.

2. **Parallel‑Trends Assumption Not Satisfied**  
   The event‑study plots show sizable and statistically significant pre‑trend divergences (Florida’s high‑dose share is already rising relative to controls). The authors argue that this reflects the “boom” phase, but the DiD identification still relies on a counterfactual that the post‑treatment trend would have continued the same trajectory absent the policy. A more credible approach would be to (i) restrict the pre‑treatment window to a period where trends are parallel (e.g., 2009‑2010), (or) (ii) employ synthetic‑control methods or a matched‑county design to balance the pre‑trend trajectory.

3. **Interpretation of Pill‑Weighting and External Validity**  
   The main effect appears only in the pill‑weighted specification; the unweighted DiD is essentially zero. While the authors correctly note that the policy’s bite is concentrated in high‑volume counties, the weighting turns the estimand into a *pill‑share* effect rather than a *county‑average* effect. The paper should more explicitly state the policy parameter being estimated (e.g., “the average change in high‑dose share for a randomly drawn pill”) and discuss how the results map onto policy relevance for a typical county or for the state as a whole.

---

**4. Suggestions**

1. **Robust Inference**  
   - Implement the **wild cluster bootstrap** (e.g., Webb 2014) with a Rademacher or Webb distribution, reporting both bootstrapped p‑values and confidence intervals.  
   - As a robustness check, treat each *county* as a cluster (allowing for heteroskedasticity) and apply **Cameron‑Miller** degrees‑of‑freedom corrections; compare results.  
   - Expand the control set: include other non‑treating states (e.g., Mississippi, Tennessee) to increase the number of clusters for clustering. Even if they are not perfect geographical matches, they can be used in a “placebo‑distribution” test.

2. **Addressing Pre‑Trends**  
   - Restrict the main DiD sample to **2009‑2012** (or later) where the pre‑trend is flatter, and present the corresponding estimate.  
   - Estimate a **synthetic‑control** version of the high‑dose share for Florida, using a weighted combination of GA/AL and perhaps additional neighboring states to better match the pre‑trend. This will provide a visual and quantitative check on the parallel‑trend assumption.  
   - Alternatively, employ a **generalized DiD** framework (Callaway & Sant’Anna 2021) that allows for heterogeneous treatment timing and explicitly models dynamic pre‑trends.

3. **Clarify the Estimand and Economic Magnitude**  
   - Provide a **back‑of‑the‑envelope calculation**: Translate the 9.3‑ppt drop in high‑dose share into the absolute number of high‑dose pills removed (e.g., *X* million 30 mg tablets) and, if possible, estimate the implied reduction in street‑level MME or potential overdose risk.  
   - Show the **distribution of effects** across counties (e.g., a histogram of county‑level DiD estimates) to illustrate heterogeneity beyond the simple high‑ vs low‑volume split.  
   - Discuss how the effect compares to the overall reduction in total oxycodone volume reported in prior literature (e.g., Alpert et al. 2018). Is the composition shift a “larger” or “complementary” channel relative to volume reductions?

4. **Robustness to Alternative Definitions**  
   - The appendix already presents thresholds of 20 mg and 40 mg. Consider a **continuous dosage‑strength outcome** (e.g., mean mg per pill) as the primary specification and report elasticities to avoid the arbitrariness of a single cutoff.  
   - Test sensitivity to **excluding the top 5 % of pill‑volume counties** (which may dominate the weighted results) and see whether the coefficient remains sizable.  
   - Check for **mis‑classification** of dosage strength (e.g., missing or erroneous “dos_str” entries) by reporting the share of transactions excluded and performing a complete‑case vs imputed analysis.

5. **Placebo and Falsification Tests**  
   - Conduct a **time‑placebo** test: assign the treatment to a pre‑policy date (e.g., July 2009) and verify that the coefficient disappears.  
   - Use **other opioid products** (e.g., hydromorphone, morphine) as falsification outcomes; there is no reason the pill‑mill law should affect their dosage composition.  
   - Verify that the effect does **not** appear in a *non‑Florida* high‑dose‑share outcome (e.g., high‑dose codeine) to rule out broader market shifts.

6. **Mechanism Discussion**  
   - The paper argues that high‑dose tablets are preferred by diversion networks. Strengthen this claim by referencing **law‑enforcement seizure data** or **street‑price reports** that explicitly link 30 mg oxycodone tablets to higher resale value.  
   - If possible, link the composition change to **mortality trends** with a lag (e.g., compare the high‑dose share trajectory to overdose death counts in the same counties). Even a simple correlation plot can illustrate the early‑warning potential.

7. **Presentation & Minor Issues**  
   - The event‑study figure is missing; add a graph with confidence bands to aid visual inspection of the “boom‑bust” pattern.  
   - In Table 2, report **cluster‑robust standard errors** with the chosen robust method (wild bootstrap) rather than the conventional ones.  
   - The “donut‑hole” specification excludes the transition months; clarify why those months are excluded and whether any policy leakage could bias the estimate.  
   - Clean up typographical inconsistencies (e.g., “pill‑weighted regressions” vs “pill‑weighted specification”).  

8. **Broader Context & Policy Implications**  
   - Discuss how the composition metric could be **integrated into existing PDMP dashboards** (e.g., as a “high‑dose share” flag).  
   - Reflect on whether similar composition shifts might be observed for **other controlled substances** (e.g., benzodiazepines) when regulation changes, suggesting a generalizable monitoring tool.  

By addressing the inference limitation, tightening the parallel‑trend assumption, and expanding the discussion of economic significance, the paper will move from an intriguing descriptive piece to a rigorous contribution that offers a novel policy‑relevant metric for opioid surveillance.
